Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

ROTY Edition 1 Volume 80: Adding To Select Positions And Continuing To Manage Risk

2018-02-16 seekingalpha
I remind readers of our biggest loser to date and why risk management has been key to ROTY`s success. (146-0)

AQXP / Aquinox Pharmaceuticals, Inc. / RA Capital Management, LLC - SCHEDULE 13G/A (Passive Investment)

2018-02-16 sec.gov
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   SCHEDULE 13G Under the Securities Exchange Act of 1934   (Amendment No. 3)*   Aquinox Pharmaceuticals, Inc.    (Name of Issuer)   Common Stock, par value $0.000001 per share   (Title of Class of Securities)   03842B101   (CUSIP Number)   December 31, 2017   (Date of Event Which Requires Filing of this Statement)   Check the appropriate box to designate the rule pursuant to which this Schedule is filed:   x Rule 13d-1(b

AQXP / Aquinox Pharmaceuticals, Inc. / RA Capital Management, LLC - SCHEDULE 13G/A (Passive Investment)

2018-02-15 sec.gov
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   SCHEDULE 13G Under the Securities Exchange Act of 1934   (Amendment No. 3)*   Aquinox Pharmaceuticals, Inc.    (Name of Issuer)   Common Stock, par value $0.000001 per share   (Title of Class of Securities)   03842B101   (CUSIP Number)   December 31, 2017   (Date of Event Which Requires Filing of this Statement)   Check the appropriate box to designate the rule pursuant to which this Schedule is filed:   x Rule 13d-1(b

AQXP / Aquinox Pharmaceuticals, Inc. / PRICE T ROWE ASSOCIATES INC /MD/ - 3G/A (Passive Investment)

2018-02-14 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) AQUINOX PHARMACEUTICALS, INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 03842B101 (CUSIP NUMBER) December 31, 2017 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [x] Rule 13d - 1(b) Rule 13d - 1(c) Rule 13d - 1(d) 1.

AQXP / Aquinox Pharmaceuticals, Inc. / PRICE T ROWE ASSOCIATES INC /MD/ - 3G/A (Passive Investment)

2018-02-14 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) AQUINOX PHARMACEUTICALS, INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 03842B101 (CUSIP NUMBER) December 31, 2017 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [x] Rule 13d - 1(b) Rule 13d - 1(c) Rule 13d - 1(d) 1.

ROTY Edition 1 Volume 79: Limited Downside Catalysts Vs. Binary Risk

2018-02-14 seekingalpha
We discuss the difference between binary catalysts and those with limited downside, utilizing two recent examples. (166-3)

ROTY Edition 1 Volume 78: Simplify Your Decision-Making And Stick To Guidelines

2018-02-13 seekingalpha
As always, readers are encouraged to do their own due diligence, manage risk appropriately, and avoid blindly following. (313-2)

This ROTY Contender Should Continue To Run Higher

2018-02-10 seekingalpha
It was recently announced that the LEADERSHIP 301 study met its enrollment threshold of 300 females and that top-line data should be disclosed in the third quarter. (4-0)

AQXP / Aquinox Pharmaceuticals, Inc. 8-K (Current Report)

2018-02-09 sec.gov
8-K     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2018     Aquinox Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter)       Delaware   001-36327   98-0542593 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.

BRIEF-Aquinox Provides Enrollment Update For Leadership 301 Clinical Trial Of Rosiptor

2018-02-09 reuters
* AQUINOX PHARMACEUTICALS INC - ENROLLMENT TARGET REACHED IN LEADERSHIP 301 CLINICAL TRIAL OF ROSIPTOR; TOPLINE DATA ON TRACK FOR Q3 2018 ANNOUNCEMENT Source text for Eikon: Further company coverage: (4-1)

AQXP / Aquinox Pharmaceuticals, Inc. / FRANKLIN RESOURCES INC - 3G/A (Passive Investment)

2018-02-05 sec.gov
aqui17a3.htm - Generated by SEC Publisher for SEC Filing           CUSIP NO. 03842B101                           13G                            Page 1 of 14                                                                                   UNITED STATES                                                          SECURITIES AND EXCHANGE COMMISSION                                                                      Washington, D.

AQXP / Aquinox Pharmaceuticals, Inc. / FRANKLIN RESOURCES INC - 3G/A (Passive Investment)

2018-02-05 sec.gov
aqui17a3.htm - Generated by SEC Publisher for SEC Filing           CUSIP NO. 03842B101                           13G                            Page 1 of 14                                                                                   UNITED STATES                                                          SECURITIES AND EXCHANGE COMMISSION                                                                      Washington, D.

ROTY Edition 1 Volume 74: A New Feature For Readers, Updates And Trades

2018-01-30 seekingalpha
So far feedback has been positive for new features added, namely the position explanation section and updated model account snapshot. (330-0)

AQXP / Aquinox Pharmaceuticals, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-01-09 fintel.io
Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) has 45 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 21,512,465 shares. Largest shareholders include Baker Brothers Advisors LP, Price T Rowe Associates Inc /md/, Franklin Resources Inc, BlackRock Inc., Goldman Sachs Group Inc, RA Capital Management, LLC, Ghost Tree Capital, LLC, Boxer Capital, LLC, Vanguard Group Inc, and Alyeska Investment Group, L. (108-0)

AQXP / Aquinox Pharmaceuticals, Inc. / BlackRock Inc. - 3G/A (Passive Investment)

2018-01-09 sec.gov
us03842b1017_010918.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 2) AQUINOX PHARMACEUTICALS INC -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 03842B101 -------------------------------------------------------- (CUSIP Number) December 31, 2017 ------------------------------------------


CUSIP: 03842B101